In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
July 23rd, 2004 | 22 | No |
Popular Name: Alsterpaullone Alsterpaullone
Find On: PubMed — Wikipedia — Google
CAS Number: 237430-03-4
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.87 | -0.89 | -13.52 | 2 | 6 | 0 | 90 | 293.282 | 1 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 2.37e-02 g/l | DrugBank-experimental |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
CCNB1-1-E | G2/mitotic-specific Cyclin B1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 35 | 0.47 | Binding ≤ 10μM |
CCNB2-1-E | G2/mitotic-specific Cyclin B2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 35 | 0.47 | Binding ≤ 10μM |
CCNB3-1-E | G2/mitotic-specific Cyclin B3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 35 | 0.47 | Binding ≤ 10μM |
CDK1-1-E | Cyclin-dependent Kinase 1 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 35 | 0.47 | Binding ≤ 10μM |
CDK2-1-E | Cyclin-dependent Kinase 2 (cluster #1 Of 5), Eukaryotic | Eukaryotes | 15 | 0.50 | Binding ≤ 10μM |
CDK5-1-E | Cyclin-dependent Kinase 5 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 40 | 0.47 | Binding ≤ 10μM |
GSK3A-1-E | Glycogen Synthase Kinase-3 Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 4 | 0.53 | Binding ≤ 10μM |
GSK3B-1-E | Glycogen Synthase Kinase-3 Beta (cluster #1 Of 7), Eukaryotic | Eukaryotes | 4 | 0.53 | Binding ≤ 10μM |
Z104294-1-O | Cyclin-dependent Kinase 5/CDK5 Activator 1 (cluster #1 Of 2), Other | Other | 40 | 0.47 | Binding ≤ 10μM |
Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 4300 | 0.34 | Functional ≤ 10μM |
Z80125-1-O | DU-145 (Prostate Carcinoma) (cluster #1 Of 9), Other | Other | 1100 | 0.38 | Functional ≤ 10μM |
Z80186-1-O | K562 (Erythroleukemia Cells) (cluster #1 Of 11), Other | Other | 1580 | 0.37 | Functional ≤ 10μM |
Z80211-1-O | LoVo (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 1000 | 0.38 | Functional ≤ 10μM |
Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 2700 | 0.35 | Functional ≤ 10μM |
Z80390-1-O | PC-3 (Prostate Carcinoma Cells) (cluster #1 Of 10), Other | Other | 1120 | 0.38 | Functional ≤ 10μM |
Z80559-1-O | U251 (cluster #1 Of 3), Other | Other | 680 | 0.39 | Functional ≤ 10μM |
Z81335-1-O | HCT-15 (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 620 | 0.40 | Functional ≤ 10μM |
Z80418-1-O | RAW264.7 (Monocytic-macrophage Leukemia Cells) (cluster #1 Of 2), Other | Other | 2200 | 0.36 | ADME/T ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
CDK1_HUMAN | P06493 | Cyclin-dependent Kinase 1, Human | 35 | 0.47 | Binding ≤ 1μM |
CDK2_HUMAN | P24941 | Cyclin-dependent Kinase 2, Human | 15 | 0.50 | Binding ≤ 1μM |
CDK5_HUMAN | Q00535 | Cyclin-dependent Kinase 5, Human | 40 | 0.47 | Binding ≤ 1μM |
Z104294 | Z104294 | Cyclin-dependent Kinase 5/CDK5 Activator 1 | 40 | 0.47 | Binding ≤ 1μM |
CCNB1_HUMAN | P14635 | G2/mitotic-specific Cyclin B1, Human | 35 | 0.47 | Binding ≤ 1μM |
CCNB2_HUMAN | O95067 | G2/mitotic-specific Cyclin B2, Human | 35 | 0.47 | Binding ≤ 1μM |
CCNB3_HUMAN | Q8WWL7 | G2/mitotic-specific Cyclin B3, Human | 35 | 0.47 | Binding ≤ 1μM |
GSK3A_HUMAN | P49840 | Glycogen Synthase Kinase-3 Alpha, Human | 4 | 0.53 | Binding ≤ 1μM |
GSK3B_HUMAN | P49841 | Glycogen Synthase Kinase-3 Beta, Human | 20 | 0.49 | Binding ≤ 1μM |
CDK1_HUMAN | P06493 | Cyclin-dependent Kinase 1, Human | 35 | 0.47 | Binding ≤ 10μM |
CDK2_HUMAN | P24941 | Cyclin-dependent Kinase 2, Human | 15 | 0.50 | Binding ≤ 10μM |
CDK5_HUMAN | Q00535 | Cyclin-dependent Kinase 5, Human | 40 | 0.47 | Binding ≤ 10μM |
Z104294 | Z104294 | Cyclin-dependent Kinase 5/CDK5 Activator 1 | 40 | 0.47 | Binding ≤ 10μM |
CCNB1_HUMAN | P14635 | G2/mitotic-specific Cyclin B1, Human | 35 | 0.47 | Binding ≤ 10μM |
CCNB2_HUMAN | O95067 | G2/mitotic-specific Cyclin B2, Human | 35 | 0.47 | Binding ≤ 10μM |
CCNB3_HUMAN | Q8WWL7 | G2/mitotic-specific Cyclin B3, Human | 35 | 0.47 | Binding ≤ 10μM |
GSK3A_HUMAN | P49840 | Glycogen Synthase Kinase-3 Alpha, Human | 4 | 0.53 | Binding ≤ 10μM |
GSK3B_HUMAN | P49841 | Glycogen Synthase Kinase-3 Beta, Human | 20 | 0.49 | Binding ≤ 10μM |
Z80125 | Z80125 | DU-145 (Prostate Carcinoma) | 1100 | 0.38 | Functional ≤ 10μM |
Z81335 | Z81335 | HCT-15 (Colon Adenocarcinoma Cells) | 620 | 0.40 | Functional ≤ 10μM |
Z80186 | Z80186 | K562 (Erythroleukemia Cells) | 1580 | 0.37 | Functional ≤ 10μM |
Z80211 | Z80211 | LoVo (Colon Adenocarcinoma Cells) | 1000 | 0.38 | Functional ≤ 10μM |
Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1240 | 0.38 | Functional ≤ 10μM |
Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 1120 | 0.38 | Functional ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 4000 | 0.34 | Functional ≤ 10μM |
Z80559 | Z80559 | U251 | 680 | 0.39 | Functional ≤ 10μM |
Z80418 | Z80418 | RAW264.7 (Monocytic-macrophage Leukemia Cells) | 2200 | 0.36 | ADME/T ≤ 10μM |
Description | Species |
---|---|
Activation of ATR in response to replication stress | |
Activation of NIMA Kinases NEK9, NEK6, NEK7 | |
Activation of the pre-replicative complex | |
AKT phosphorylates targets in the cytosol | |
APC truncation mutants have impaired AXIN binding | |
APC/C:Cdc20 mediated degradation of Cyclin B | |
AXIN missense mutants destabilize the destruction complex | |
Beta-catenin phosphorylation cascade | |
CDK-mediated phosphorylation and removal of Cdc6 | |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |
Condensation of Prometaphase Chromosomes | |
Condensation of Prophase Chromosomes | |
Constitutive PI3K/AKT Signaling in Cancer | |
CRMPs in Sema3A signaling | |
Cyclin A/B1 associated events during G2/M transition | |
Cyclin A:Cdk2-associated events at S phase entry | |
Cyclin B2 mediated events | |
Cyclin E associated events during G1/S transition | |
DARPP-32 events | |
Degradation of beta-catenin by the destruction complex | |
Depolymerisation of the Nuclear Lamina | |
disassembly of the destruction complex and recruitment of AXIN to the membrane | |
DNA Damage/Telomere Stress Induced Senescence | |
E2F mediated regulation of DNA replication | |
E2F-enabled inhibition of pre-replication complex formation | |
ERK1 activation | |
Factors involved in megakaryocyte development and platelet production | |
G0 and Early G1 | |
G1/S-Specific Transcription | |
G2 Phase | |
G2/M DNA replication checkpoint | |
Golgi Cisternae Pericentriolar Stack Reorganization | |
Loss of Nlp from mitotic centrosomes | |
Loss of proteins required for interphase microtubule organization from the ce | |
MASTL Facilitates Mitotic Progression | |
Meiotic recombination | |
misspliced GSK3beta mutants stabilize beta-catenin | |
Nuclear Pore Complex (NPC) Disassembly | |
Orc1 removal from chromatin | |
p53-Dependent G1 DNA Damage Response | |
Phosphorylation of Emi1 | |
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 | |
Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 com | |
Phosphorylation of the APC/C | |
Polo-like kinase mediated events | |
Recruitment of mitotic centrosome proteins and complexes | |
Recruitment of NuMA to mitotic centrosomes | |
Regulation of APC/C activators between G1/S and early anaphase | |
Regulation of HSF1-mediated heat shock response | |
Regulation of PLK1 Activity at G2/M Transition | |
Resolution of Sister Chromatid Cohesion | |
S33 mutants of beta-catenin aren't phosphorylated | |
S37 mutants of beta-catenin aren't phosphorylated | |
S45 mutants of beta-catenin aren't phosphorylated | |
SCF(Skp2)-mediated degradation of p27/p21 | |
Senescence-Associated Secretory Phenotype (SASP) | |
T41 mutants of beta-catenin aren't phosphorylated | |
truncations of AMER1 destabilize the destruction complex | |
XBP1(S) activates chaperone genes |
No pre-computed analogs available. Try a structural similarity search.